sorafenib has been researched along with Angiosarcoma in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andersen, NJ; Baker, LH; Boguslawski, EA; Dawes, MJ; Duesbery, NS; Dykema, KJ; Froman, RE; Furge, KA; Kamstock, DA; Kitchell, BE; Krivochenitser, RI; Nickoloff, BJ; Thomas, DG | 1 |
| Bal-Mahieu, C; Baldeyrou, B; Bay, JO; Blay, JY; Bompas, E; Chevreau, C; Clisant, S; Fournier, C; Italiano, A; Lansiaux, A; Le Cesne, A; Penel, N; Piperno-Neumann, S; Ray-Coquard, I; Robin, YM | 1 |
| Dill, MT; Djonov, V; Heim, MH; Hlushchuk, R; Makowska, Z; Quagliata, L; Rothweiler, S; Semela, D; Terracciano, L | 1 |
| Cozzio, A; Donghi, D; Dummer, R | 1 |
| Sleijfer, S | 1 |
| Bay, JO; Blay, JY; Bompas, E; Bousquet, G; Chevreau, C; Clisant, S; Collard, O; Cupissol, D; Fournier, C; Gauthier, E; Isambert, N; Italiano, A; Le Cesne, A; Lemaitre, L; Penel, N; Piperno-Neumann, S; Ray-Coquard, I; Robin, YM | 1 |
| Ishii, M; Kamo, R; Kobayashi, H; Kumei, A; Tamiya, H; Yanagihara, S | 1 |
| Fujisawa, A; Matsumura, Y; Miyachi, Y; Ono, S; Tanioka, M; Tanizaki, H | 1 |
2 trial(s) available for sorafenib and Angiosarcoma
| Article | Year |
|---|---|
Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Enzyme-Linked Immunosorbent Assay; Hemangioendothelioma, Epithelioid; Hemangiosarcoma; Humans; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Endpoint Determination; Female; Hemangiosarcoma; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
6 other study(ies) available for sorafenib and Angiosarcoma
| Article | Year |
|---|---|
Pharmacologic inhibition of MEK signaling prevents growth of canine hemangiosarcoma.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Proliferation; Diphenylamine; Disease Models, Animal; Dogs; Drug Screening Assays, Antitumor; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Hemangiosarcoma; Humans; Mice; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
Generation of a murine hepatic angiosarcoma cell line and reproducible mouse tumor model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Gene Expression Regulation, Neoplastic; Hemangiosarcoma; Immunohistochemistry; Liver; Liver Neoplasms; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Microscopy, Electron; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Receptor, Notch1; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Tumor Burden | 2015 |
Complete remission in a patient with multifocal metastatic cutaneous angiosarcoma with a combination of paclitaxel and sorafenib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Head and Neck Neoplasms; Hemangiosarcoma; Humans; Male; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Remission Induction; Skin Neoplasms; Sorafenib; Treatment Outcome | 2010 |
Phase II studies in soft tissue sarcoma: time for reappraisal.
Topics: Antineoplastic Agents; Benzenesulfonates; Female; Hemangiosarcoma; Humans; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2012 |
Partial response of angiosarcoma of the scalp to sorafenib: association with decreased expression of vascular endothelial growth factors and their receptors.
Topics: Antineoplastic Agents; Head and Neck Neoplasms; Hemangiosarcoma; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Scalp; Skin Neoplasms; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factors | 2012 |
Angiosarcoma of the scalp successfully treated with a single therapy of sorafenib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Female; Head and Neck Neoplasms; Hemangiosarcoma; Humans; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Scalp; Skin Neoplasms; Sorafenib; Treatment Outcome | 2012 |